Because both 22RV1 and LNCaP cells harbor inactivating mutations in BRCA1/2 genes, we next examined whether MALAT1 can modulate the HR pathway in HR-proficient prostate cancer cells. This evidence concerns the gene BRCA1 and Familial prostate cancer.